M 6620

Drug Profile

M 6620

Alternative Names: Captisol® enabled VX 970; M6620; VX970

Latest Information Update: 09 Mar 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Vertex Pharmaceuticals
  • Developer Merck KGaA; National Cancer Institute (USA)
  • Class Antineoplastics
  • Mechanism of Action ATR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Urogenital cancer
  • Phase I/II Small cell lung cancer; Solid tumours
  • Preclinical Acute myeloid leukaemia

Most Recent Events

  • 11 Jan 2017 VX 970 licensed to Merck KGaA worldwide
  • 01 Dec 2016 Preclinical trials in Acute myeloid leukaemia in USA (IV) before December 2016
  • 15 Nov 2016 Pharmacodynamic results from a preclinical trial in Solid tumours presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top